表皮生长因子受体-酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌的效果分析  

Analysis on Effect of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Combined with Chemotherapy in Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：吴敏燕 李荣岗[2] 张鑫[3] 邱轶芳 卢怀笋 李华汉 杨文丽[2] 陆文洁 Wu Minyan;Li Ronggang;Zhang Xin;Qiu Yifang;Lu Huaisun;Li Huahan;Yang Wenli;Lu Wenjie(School of Basic Medicine,Guangdong Jiangmen Chinese Medicine College,Jiangmen 529000,Guangdong Province,China;Department of Pathology,Jiangmen Central Hospital2,Jiangmen 529000,Guangdong Province,China;Medical Research Center,Jiangmen Central Hospital Jiangmen 529000,Guangdong Province,China)

机构地区：[1]广东江门中医药职业学院基础医学院,广东江门529000 [2]江门市中心医院病理科,广东江门529000 [3]江门市中心医院医学研究中心,广东江门529000

出　　处：《中国社区医师》2023年第27期44-46,共3页Chinese Community Doctors

基　　金：广东省江门市科技计划项目(编号:2020YLE005)。

摘　　要：目的:探讨表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)联合化疗治疗晚期非小细胞肺癌(NSCLC)的效果。方法:选取2010年1月—2015年12月江门市中心医院收治的50例晚期NSCLC患者作为研究对象,采用随机数字表法分为对照组与研究组,各25例。对照组采用常规化疗,研究组在对照组基础上应用EGFR-TKI治疗。比较两组治疗效果。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P<0.001)。治疗前,两组癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、糖类抗原125(CA125)水平比较,差异无统计学意义(P>0.05);治疗后,研究组CEA、NSE、CA125水平低于对照组,差异有统计学意义(P<0.001)。治疗前,两组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC比较,差异无统计学意义(P>0.05);治疗后,两组FEV1、FVC、FEV1/FVC高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.001)。研究组中位总生存期、无进展生存期长于对照组,差异有统计学意义(P<0.05)。结论:EGFR-TKI联合化疗治疗晚期NSCLC的效果显著,可改善患者肿瘤标志物水平及肺功能,延长其生存期。Objective:To investigate the effects of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)in combination with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:From January 2010 to December 2015,50 patients with advanced NSCLC admitted to the Jiangmen Central Hospital Medicine College were selected as study subjects.They were divided into control group and study group according to random number table method,with 25 cases in each group.The control group was treated with conventional chemotherapy,and the study group was treated with EGFR-TKI on the basis of control group.The treatment effects of the two groups were compared.Results:The total effective rate of treatment in the study group was higher than that in the control group,and the difference was statistically significant(P<0.001).Before treatment,there was no statistically significant difference in the levels of carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)and carbohydrate antigen 125(CA125)between two groups(P>0.05).After treatment,the levels of CEA,NSE and CA125 in the study group were lower than those in the control group,and the difference was statistically significant(P<0.001).Before treatment,there was no statistically significant difference in the forced expiratory volume in 1 s(FEV1),forced vital capacity(FVC),FEV1/FVC between two groups(P>0.05).After treatment,FEV1、FVC、FEV1/FVC in two groups were higher than those before treatment,and the study group was higher than the control group,and the difference was statistically significant(P<0.001).The median overall survival and progression-free survival in the study group were longer than those in the control group,and the difference was statistically significant(P<0.05).Conclusion:EGFR-TKI combined with chemotherapy has a significant effect in the treatment of advanced NSCLC,which can improve tumor marker levels and lung function,and prolong the survival of patients.

关 键 词：非小细胞肺癌 表皮生长因子受体-酪氨酸激酶抑制剂 肿瘤标志物 生存期 

分 类 号：R734.2[医药卫生—肿瘤]